Seattle Cancer Care Alliance (SCCA) clinicians’ clinical oncology results to be presented at ASCO’s annual meeting in 2021

SEATTLE – (COMMERCIAL THREAD) –Seattle Cancer Care Alliance (SCCA) today announced presentations from the organization’s clinicians to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting from June 4 to 8, 2021.

SCCA clinicians have contributed to studies of several types of cancer spanning the entire continuum of cancer care – from prevention to diagnosis to treatment. Presentations will highlight results from Phase 1 trials, CAR T therapy, breast cancer, bladder cancer, non-small cell lung cancer and hematologic cancers. In addition, there are numerous studies on the impact of the COVID-19 pandemic on cancer diagnosis, clinical care and clinical trials in oncology. SCCA clinical researchers have also contributed to new findings related to genetic profiling, prostate needle biopsy pathology, and precision therapy for salivary gland cancer.

“The SCCA is a leader in groundbreaking clinical trials turning scientific discoveries into exciting new treatments that often change the way cancer care is delivered,” said Nancy Davidson, MD, president and executive director of the Seattle Cancer Care Alliance and former president of ASCO. “The work presented by our physician-researchers at ASCO 2021 once again demonstrates these ongoing efforts to improve the way patients are treated and advance multidisciplinary cancer care. ”

More information on SCCA presentations and publications at ASCO is available at: https://www.seattlecca.org/conference/asco-2021

Presentation details:

Breast cancer screening in carriers of the pathogenic variants ATM, CHEK2 and PALB2: a comparative modeling analysis.

Abstract: 10500

Author of SCCA: Kathryn P. Lowry, MD

Impact of disruptions in breast cancer control due to the COVID-19 pandemic on breast cancer mortality in the United States: estimates from collaborative simulation modeling.

Abstract: 6562

Author of SCCA: Kathryn P. Lowry, MD

Adoptive immunotherapy phase I study for advanced MUC1 * positive breast cancer with autologous T cells designed to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1 *).

Abstract: TPS2663

Author of SCCA: Jennifer M. Specht, MD and David G. Maloney, MD, PhD

The efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR + / estrogen receptor (ER) + breast cancer in a clinical study international phase 2.

Abstract: 1020

Author of SCCA: Hannah M. Linden, MD

AMEERA-1: Phase 1/2 study of amenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER + / factor receptor Human epidermal growth 2-negative (HER2-) metastatic breast cancer (mBC).

Abstract: 1058

Author of SCCA: Hannah M. Linden, MD

Case-Based Panel: Optimizing Precision Therapy in Salivary Gland Cancers with a Look to the Future

SCCA speaker: Cristina P. Rodriguez, MD

PrE0807: A phase Ib feasibility study of neoadjuvant nivolumab (N) without or with lirilumab (L) in patients ineligible for cisplatin (pts) with muscular invasive bladder cancer (MCDI).

Abstract: 4518

Author of SCCA: Petros Grivas, MD, Ph.D.

Maintenance first-line (1L) Avelumab plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): analysis of time to end of next-line treatment in JAVELIN Bladder 100.

Abstract: 4525

Author of SCCA: Petros Grivas, MD, Ph.D.

Fluciclovine PET / CT (FACBC) in Oligometastatic Prostate Cancer (Flu-BLAST-PC).

Abstract: TPS5099

Author of SCCA: Risa L. Wong, Jonathan L. Wright, MD, MS, Heather H. Cheng, MD, PhD and Evan Y. Yu, MD

Clinical accuracy of information extracted from prostate biopsy pathology reports using natural language processing.

Abstract: 1557

Author of SCCA: Risa L. Wong and John L. Gore, MD, MS, FACS

Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: a comprehensive genomic profiling study (CGP).

Abstract: 3130

Author of SCCA: Petros Grivas, MD, Ph.D.

Concordance of DNA damage repair (DDR) gene mutations in matched primary and metastatic prostate cancer (PC) samples.

Abstract: 5020

Author of SCCA: Michael T. Schweizer, MD, Evan Y. Yu, MD and Colin C. Pritchard, MD, PhD

Case-based panel: Optimizing the management of urothelial cancer from organ-confined disease to metastatic disease: a multidisciplinary approach

SCCA Moderator / President: Evan Y. Yu, MD

Oral session: Germline genetic testing for prostate cancer

Discussing the SCCA: Colin C. Pritchard, MD, PhD

The product type CD19 CAR T-cell has an independent impact on the severity of CRS and ICANS in patients with aggressive NHL.

Abstract: 7532

Author of SCCA: Jordan Gauthier, MD, M.Sc., Mazyar Shadman, MD, MPH, David G. Maloney, MD, PhD and Cameron J. Turtle, MBBS, PhD, FRACP, FRCPA

Efficacy of clinical breast examination in women surviving irradiated thorax from childhood Hodgkin lymphoma (HL).

Abstract: 10028

Author of SCCA: Janie M. Lee, MD, M.Sc.

Demographics, Outcomes, and Risk Factors for Patients (Pts) with Sarcoma and COVID-19: A Multi-Institutional Cohort Analysis.

Abstract: 11523

Author of SCCA: Michael J. Wagner, MD

Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after more than five years of follow-up.

Abstract: 9517

Author of SCCA: Paul Nghiem, MD, PhD

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in non-small cell lung cancer (NSCLC) resistant to EGFR inhibitors and mutated to EGFR (EGFRm).

Abstract: 9007

Author of SCCA: Christina S. Baik, MD, MPH

Oral session: Emerging trends in radiation for localized lung cancers

SCCA speaker: Ramesh Rengan, MD, Ph.D.

Phase 1b dose escalation study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of GS-3583, an Fc agonist FLT3 fusion protein, in patients with advanced solid tumors.

Abstract: TPS3147

Author of SCCA: John A. Thompson, MD

First phase I / II human study of CYT-0851, a first-class inhibitor of homologous recombination mediated by RAD51 in patients with advanced solid and hematologic cancers.

Abstract: 3006

Author of SCCA: Ryan C. Lynch, MD

Training session: COG perspective on the impact of COVID-19 on pediatric oncology clinical trials and their implications for the future

SCCA speaker: Douglas S. Hawkins, MD

Discussion poster session: COVID-19 and cancer: learning as you go

SCCA speaker: Petros Grivas, MD, Ph.D.

Cancer Diagnosis and Adverse Financial Events: Evidence from Credit Reports.

Abstract: 6504

Author of SCCA: Veena Shankaran, MD, MS

Choosing Wisely: Selecting the Right Population at the Right Time for DNA Damaging Therapy

SCCA speaker: Elizabeth M. Swisher, MD

About Seattle Cancer Care Alliance

The Seattle Cancer Care Alliance brings together leading cancer research teams and specialists from Fred Hutch, Seattle Children’s and UW Medicine – an extraordinary group whose sole purpose is the pursuit of better, longer and richer lives for our patients. . Based in Seattle’s South Lake Union neighborhood, the Seattle Cancer Care Alliance has nine clinical care sites in the region, including a medical oncology clinic at EvergreenHealth in Kirkland; hematology / medical oncology and infusion services at Overlake Medical Center in Bellevue, medical and radiation oncology clinics at UW Medical Center – Northwest Seattle and medical oncology services at SCCA Issaquah, as well as network affiliations with hospitals in five states. For more information on SCCA, visit www.seattlecca.org.


Source link

About Hector Hedgepeth

Hector Hedgepeth

Check Also

Akoya Announces Publication of MITER Study, the First Multi-Institutional Analytical Demonstration of a Space Biology Workflow, in the Journal for ImmunoTherapy of Cancer

MARLBOROUGH, Mass., July 19, 2021 (GLOBE NEWSWIRE) – Akoya Biosciences Inc, (Nasdaq: AKYA) The Spatial …

Leave a Reply

Your email address will not be published. Required fields are marked *